Search Medical Condition
Please enter condition
Please choose location

Harefield, United Kingdom Clinical Trials

A listing of Harefield, United Kingdom clinical trials actively recruiting patients volunteers.

RESULTS

Found (146) clinical trials

Intravenous Iron Treatment in Patients With Heart Failure and Iron Deficiency: IRONMAN

Chronic heart failure (CHF) is a very common medical problem. Despite improvements in treatment, many patients suffer limiting symptoms of shortness of breath and fatigue. Hospitalisation for CHF is common and life expectancy reduced. Many patients with CHF have a deficiency of iron (low iron levels or cannot use iron ...

Phase

0.0 miles

Learn More »

International Registry Study of Neutral Lipid Storage Disease (NLSD) / Triglyceride Deposit Cardiomyovasculopathy (TGCV) and Related Diseases

Since NLSD is a rare disease, its clinical manifestation and clinical course have not been sufficiently clarified. Also, the number of patients in each country is limited. As such, it is considered difficult to fully investigate this disease without international collaboration. Therefore, we have established the International Registry of NLSD ...

Phase N/A

0.25 miles

Learn More »

Assessment of Heart and Heart-Lung Transplant Patient Outcomes Following Pulmonary Rehabilitation

At present, a specific community based rehabilitation programme for lung or heart-lung transplant recipients does not exist. 160 hospitals throughout the United Kingdom (UK) offer pulmonary rehabilitation programmes. The programmes operate under evidence-based guidelines as outlined by the Chartered Society of Physiotherapy. Increasing evidence shows that rehabilitation programmes help improve ...

Phase

0.25 miles

Learn More »

Stimulation Of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in Non-Responders and Previously Untreatable Patients (SOLVE CRT)

The WiSE-LV System is an implantable cardiac pacing system capable of delivering pacing energy to the left ventricle of the heart without using a pacing lead.

Phase

0.25 miles

Learn More »

European Trial of Pirfenidone in BOS A European Multi-center Study

Title of the study: A European multi-centre, randomised, double-blind placebo-controlled trial of Pirfenidone in bronchiolitis-obliterans-syndrome grade 1-2 in lung transplant recipients Study design: Randomized double blinded, placebo controlled study. Eligible patients are to be randomized in a 1:1 ratio to receive either Pirfenidone 2403 mg/d or the matching placebo treatment ...

Phase

0.31 miles

Learn More »

A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma

This is a Phase I clinical study of IMCgp100 in patients with advanced melanoma. In the Phase I FIH study of IMCgp100 in advanced melanoma, a dose escalation was conducted with IMCgp100 administered on a weekly basis (Middleton, 2015). In this study, the MTD when IMCgp100 is administered on a ...

Phase

1.83 miles

Learn More »

Phase 2 Study of Tucatinib vs Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

A randomized, international, multi-center, double-blinded study in patients with progressive unresectable locally advanced or metastatic HER2+ breast cancer who have had prior treatment with trastuzumab, pertuzumab and T-DM1. Patients will be randomized in a 2:1 ratio to receive tucatinib or placebo in combination with capecitabine and trastuzumab. Stratification factors include ...

Phase

1.83 miles

Learn More »

A Phase III Parallel Group Study Comparing the Efficacy Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

A once-daily 'closed' triple FDC therapy of FF/UMEC/VI via a single ELLIPTA dry powder inhaler (DPI) is being developed by GlaxoSmithKline (GSK) with the aim of providing a new treatment option for the management of asthma by improving lung function, health-related quality of life (HRQoL) and symptom control over established ...

Phase

1.83 miles

Learn More »

A Study of the Anti-PD1 Antibody PDR001 in Combination With Dabrafenib and Trametinib in Advanced Melanoma

To evaluate the safety and efficacy of the combination of an anti-PD-1 antibody (PDR001), a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in unresectable or metastatic BRAF V600 mutant melanoma

Phase

1.83 miles

Learn More »